Kinnear Pharmaceuticals is a preclinical-stage biotechnology company developing Ceragenin-based anti-infective and anti-inflammatory therapies, with its lead candidate CSA-131 aimed at difficult infections associated with cystic fibrosis. The Las Vegas company’s proprietary platform, based on research invented at Brigham Young University, uses synthetic non-peptide molecules modeled on the innate immune peptide LL-37. Kinnear is a subsidiary of N8 Biosciences and received FDA Qualified Infectious Disease Product designation for CSA-131 in 2023.
Qualified Infectious Disease Product (QIDP) Designation
Compliance program
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
AvantGuardCornell University spinout AvantGuard develops antimicrobial chemistry for protecting skin, medical devices, and other surfaces from pathogens and biofilms. Founded as Halomine in 2018, the company built its Avantamine platform to mimic the pathogen-fighting properties of taurine chloramine while offering a reported three- to five-year shelf life and less corrosion and irritation than conventional chlorine products. Its current development focus includes solutions for the drug-resistant fungal pathogen Candida auris.ITHACA, NY
Hsiri TherapeuticsHsiri Therapeutics is a biotechnology company developing therapies for infections caused by drug-resistant bacteria and fungi, with particular attention to tuberculosis and nontuberculous mycobacterial disease. Its discovery work originated at the University of Notre Dame and Montana State University, and its research laboratories are in South Bend, Indiana, alongside collaborations in Montana and Singapore. The company has received support from the Department of Defense and the National Institutes of Health and has entered research and licensing collaborations with Shionogi.MEDIA, PA